drugset / Trial / NCT00004104
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
RandomizedTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients who have stage III melanoma.
Timeline
- Start
- 1998-06
- Primary completion
- 2000-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | — |
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Subcutaneous |
| Subject | polyvalent melanoma vaccine | Vaccine | — | — |